Loading…
Reported covered position: 91-93 Policy Advisor, Senate Democratic Policy Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NUTRINOVA via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
GRAS reform/food safety legislation and FDA regulations relating to food safety.
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
Source: Senate LDA
| STANDARDS COORDINATING BODY FOR REGENERATIVE MEDICINE |
| 17 |
| 2019–2022 |
| UPS | 16 | 2011–2014 |
| THE BIOSIMILARS FORUM | 15 | 2015–2018 |
| NOMI HEALTH | 14 | 2021–2024 |
| MED-IQ | 12 | 2009–2012 |
| PROVEN PHARMACEUTICALS (F/K/A NOVIS PHARMACEUTICALS) | 9 | 2012–2013 |
| TEVA PHARMACEUTICALS USA INC | 9 | 2019–2020 |
| THERMO FISHER SCIENTIFIC INC. | 9 | 2015–2017 |
| Safecor Health, LLC | 8 | 2012–2013 |
| SCIPHER MEDICINE CORPORATION | 7 | 2022–2024 |
| ACTAVIS, INC. | 6 | 2014–2015 |
| BENETRENDS, INC. | 6 | 2010–2011 |
| COMPASS PATHWAYS PLC | 6 | 2024–2025 |
| ALLIANCE FOR COMMUNITY HEALTH PLANS | 5 | 2009–2010 |
| ARROW INTERNATIONAL, INC. | 5 | 2014 |
| ASCEND PERFORMANCE MATERIALS | 5 | 2020–2021 |
| CELL THERAPEUTICS INC | 5 | 2010–2011 |
| DEUTSCHE PROCESS | 5 | 2019 |
| ECOLAB, INC. | 5 | 2025–2026 |
| EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS | 5 | 2024 |
| LIFE TECHNOLOGIES CORPORATION | 5 | 2010–2011 |
| NORTHRUP GRUMMAN SYSTEMS CORPORATION | 5 | 2017 |
| NUTRINOVA | 5 | 2025–2026 |
| UL LLC D/B/A UL SOLUTIONS | 5 | 2023–2026 |
| BASF CORPORATION | 4 | 2012–2013 |
| BLANDFORD BIOTECH CORPORATION | 4 | 2021–2022 |
| KINDERFARMS, LLC | 4 | 2025 |
| KRATOM TRADE ASSOCIATION | 4 | 2018 |
| Q THERAPEUTICS, INC. | 4 | 2010 |
| SOUND PHARMACEUTICALS, INC. | 4 | 2026 |
| TRIAD LIFE SCIENCES, INC. | 4 | 2022 |
| ASSOCIATION OF CRITICAL CARE TRANSPORT | 3 | 2012 |
| BIOTECHNOLOGY INDUSTRY ORGANIZATION | 3 | 2009 |
| CAPITOL BRIDGE LLC | 3 | 2020 |
| CLEANWELL, LLC | 3 | 2020 |
| EAZE SOLUTIONS, INC. | 3 | 2018–2019 |
| FOUNDATION MEDICINE, INC. | 3 | 2010 |
| JOHNSON FOODS, LLC | 3 | 2022–2024 |
| NALU BIO, INC. | 3 | 2023 |
| NOVEOME BIOTHERAPEUTICS | 3 | 2020 |
| PHADIA US INC. | 3 | 2015 |
| PRIDE MOBILITY PRODUCTS CORPORATION | 3 | 2020–2021 |
| VIBRENT HEALTH | 3 | 2021 |
| ADJUVANT GLOBAL ADVISERS, LLC | 2 | 2019 |
| ASHLAND INC | 2 | 2012–2013 |
| ASSOCIATION OF ORGAN PROCUREMENT ORGANIZATIONS | 2 | 2021 |
| AYA HEALTHCARE | 2 | 2021 |
| ESSENCE CONSULTING, INC. D/B/A ESSENCE PATIENT SOLUTIONS | 2 | 2021 |
| INCEPTION FERTILITY, LLC | 2 | 2025 |
| NATIONAL ASSOCIATION OF EMS PHYSICIANS | 2 | 2016–2017 |
| PATIENT RIGHTS WATCH | 2 | 2013 |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK | 1 | 2023 |
| BIOMARIN PHARMACEUTICAL INC. | 1 | 2024 |
| BLUEBIRD STRATEGIES | 1 | 2023 |
| CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. | 1 | 2025 |
| ENDO PHARMACEUTICALS INC | 1 | 2010 |
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; S. 4744/H.R. 9237 - the Take Care of Americas Veterans Act.
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Take Care of America’s Veterans Act
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; S. 4744/H.R. 9237 - the Take Care of Americas Veterans Act.
Department of Defense Appropriations Act, 2027
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Department of Defense Appropriations Act, 2027
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Take Care of America’s Veterans Act
Client: SOUND PHARMACEUTICALS, INC. · Firm: HOLLAND & KNIGHT LLP
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; S. 4744/H.R. 9237 - the Take Care of Americas Veterans Act.
Advancing Research for Chronic Pain Act of 2026
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies and future legislation related to drug labeling and chronic pain surveillance; S. 5041 - Advancing Research for Chronic Pain Act.
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
SAFE Sunscreen Standards Act
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
SAFE Sunscreen Standards Act
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in the Coronavirus Aid, Relief, and Economic Security (CARES Act; Public Law 116-136); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA); the SAFE Sunscreen Standards Act (H.R. 3686).
SAFE Sunscreen Standards Act
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing.
Department of Defense Appropriations Act, 2026
Client: CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. · Firm: HOLLAND & KNIGHT LLP
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology.
Department of Defense Appropriations Act, 2026
Client: CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. · Firm: HOLLAND & KNIGHT LLP
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology; H.R.4553 - Energy and Water Development and Related Agencies Appropriations Act, 2026 - issues related to quantum technology.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: KINDERFARMS, LLC · Firm: HOLLAND & KNIGHT LLP
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in the Coronavirus Aid, Relief, and Economic Security (CARES Act; Public Law 116-136); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA); the SAFE Sunscreen Standards Act (H.R. 3686).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: KINDERFARMS, LLC · Firm: HOLLAND & KNIGHT LLP
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); FDA rulemaking on ultraprocessed food.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Energy and Water Development and Related Agencies Appropriations Act, 2026
Client: CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. · Firm: HOLLAND & KNIGHT LLP
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology; H.R.4553 - Energy and Water Development and Related Agencies Appropriations Act, 2026 - issues related to quantum technology.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS INC · Firm: HOLLAND & KNIGHT LLP
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: KINDERFARMS, LLC · Firm: HOLLAND & KNIGHT LLP
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); FDA rulemaking on ultraprocessed food.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in the Coronavirus Aid, Relief, and Economic Security (CARES Act; Public Law 116-136); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA); the SAFE Sunscreen Standards Act (H.R. 3686).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: KINDERFARMS, LLC · Firm: HOLLAND & KNIGHT LLP
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256).
Department of Defense Appropriations Act, 2026
Client: CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. · Firm: HOLLAND & KNIGHT LLP
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology.
Department of Defense Appropriations Act, 2026
Client: CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. · Firm: HOLLAND & KNIGHT LLP
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology; H.R.4553 - Energy and Water Development and Related Agencies Appropriations Act, 2026 - issues related to quantum technology.
FDA Modernization Act 3.0
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: NOMI HEALTH · Firm: HOLLAND & KNIGHT LLP
Vaccine dissemination and distribution; pandemic vaccine and testing policies; funding for COVID testing; healthcare payment transparency; HR 4531/S.393 - The SUPPORT Act.
Support for Patients and Communities Reauthorization Act
Client: NOMI HEALTH · Firm: HOLLAND & KNIGHT LLP
Secure/recoup funding for COVID testing; healthcare payment transparency; HR 4531/S.393 - The SUPPORT Act; find co-sponsors for Improving Seniors Timely Access to Care Act, S. 4532/H.R. 8702.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Support for Patients and Communities Reauthorization Act
Client: PROTECTING ACCESS TO PAIN RELIEF COALITION · Firm: HOLLAND & KNIGHT LLP
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Federal Kratom Consumer Protection Act
Client: JOHNSON FOODS, LLC · Firm: HOLLAND & KNIGHT LLP
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Federal Kratom Consumer Protection Act
Client: JOHNSON FOODS, LLC · Firm: HOLLAND & KNIGHT LLP
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Federal Kratom Consumer Protection Act
Client: JOHNSON FOODS, LLC · Firm: HOLLAND & KNIGHT LLP
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Federal Kratom Consumer Protection Act
Client: JOHNSON FOODS, LLC · Firm: HOLLAND & KNIGHT LLP
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Improving Seniors’ Timely Access to Care Act of 2024
Client: NOMI HEALTH · Firm: HOLLAND & KNIGHT LLP
Secure/recoup funding for COVID testing; healthcare payment transparency; HR 4531/S.393 - The SUPPORT Act; find co-sponsors for Improving Seniors Timely Access to Care Act, S. 4532/H.R. 8702.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); skin cancer prevention for outdoor workers; Cancer Moonshot initiative; use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); skin cancer prevention for outdoor workers; use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION · Firm: HOLLAND & KNIGHT LLP
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); implementation of the National Academies of Science (NAS) report on sunscreen; skin cancer prevention for outdoor workers; Cancer Moonshot initiative; use of sunscreen in schools to prevent sunburns in children.
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
CONNECT for Health Act of 2023
Client: DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE · Firm: HOLLAND & KNIGHT LLP
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SOUND PHARMACEUTICALS, INC. via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
Issues related to hearing loss and treatment.
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; S. 4744/H.R. 9237 - the Take Care of Americas Veterans Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ECOLAB, INC. via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
Drug supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
Policies and future legislation related to drug labeling and chronic pain surveillance; S. 5041 - Advancing Research for Chronic Pain Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2026 · third_quarter · Q3
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2026 · first_quarter · 1A
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NUTRINOVA via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
GRAS reform/food safety legislation and FDA regulations relating to food safety.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ECOLAB, INC. via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
Biologics manufacturing.
Filing targets: Food & Drug Administration (FDA)
SOUND PHARMACEUTICALS, INC. via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Issues related to hearing loss and treatment; H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9495 - Department of Defense Appropriations Act, 2027.
VIATRIS INC via HOLLAND & KNIGHT LLP
2026 · second_quarter · Q2
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
UL LLC D/B/A UL SOLUTIONS via HOLLAND & KNIGHT LLP
2026 · second_quarter · 2T
Lithium-ion battery safety; USMCA; AI; Trade, Data Centers, refrigerants, and medical devices.
Filing targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Implementation of the sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2027 appropriations for the Food and Drug Administration; use of sunscreen in schools to prevent sunburns in children; FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SOUND PHARMACEUTICALS, INC. via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Issues related to hearing loss and treatment.
Issues related to hearing loss and treatment.
Issues related to hearing loss and treatment.
SOUND PHARMACEUTICALS, INC. via HOLLAND & KNIGHT LLP
2026 · first_quarter · RR
Issues related to hearing loss and treatment.
Issues related to hearing loss and treatment.
Issues related to hearing loss and treatment.
NUTRINOVA via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Issues related to food.
ECOLAB, INC. via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Discussions regarding drug manufacturing regulations.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UL LLC D/B/A UL SOLUTIONS via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
Lithium-ion battery safety; E-Bikes, Energy Policy Conservation Act (EPCA) reform; USMCA; AI; Autonomous Vehicles; cybersecurity.
Filing targets: HOUSE OF REPRESENTATIVES
VIATRIS INC via HOLLAND & KNIGHT LLP
2026 · first_quarter · Q1
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · Q4
Sunscreen provisions in the reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing for over-the-counter drugs; FDA Modernization Act 3.0 (S. 355; H.R. 2821).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · Q4
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ECOLAB, INC. via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · Q4
Issues involving animal health.
Filing targets: Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NUTRINOVA via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · Q4
Issues related to food.
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · Q4
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NUTRINOVA via HOLLAND & KNIGHT LLP
2025 · fourth_quarter · RR
Issues related to food additives.
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2025 · third_quarter · Q3
Reauthorization of the Food and Drug Administration (FDA) Over-the-Counter Monograph User Fee Act (OMUFA); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; the SAFE Sunscreen Standards Act (H.R. 3686); FDA policy on animal testing.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
KINDERFARMS, LLC via HOLLAND & KNIGHT LLP
2025 · third_quarter · 3T
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); FDA rulemaking on ultraprocessed food.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2025 · third_quarter · Q3
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2025 · third_quarter · Q3
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
ECOLAB, INC. via HOLLAND & KNIGHT LLP
2025 · third_quarter · Q3
Issues involving animal health.
Filing targets: Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CLARK STREET ASSOCIATES ON BEHALF OF IONQ, INC. via HOLLAND & KNIGHT LLP
2025 · third_quarter · Q3
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology.
H.R.4016, S.2572 - Department of Defense Appropriations Act, 2026 - issues related to quantum technology; H.R.4553 - Energy and Water Development and Related Agencies Appropriations Act, 2026 - issues related to quantum technology.
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
KINDERFARMS, LLC via HOLLAND & KNIGHT LLP
2025 · second_quarter · Q2
Over-the-counter (OTC) drug and food safety and nutrition issues; OTC monograph User Fee Act (OMUFA) reauthorization; Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2025 · second_quarter · Q2
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in the Coronavirus Aid, Relief, and Economic Security (CARES Act; Public Law 116-136); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the Fiscal Year 2026 appropriations for the Food and Drug Administration (FDA) (H.R. 4121 and S. 2256); use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA); the SAFE Sunscreen Standards Act (H.R. 3686).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2025 · second_quarter · Q2
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2025 · second_quarter · Q2
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
INCEPTION FERTILITY, LLC via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Policies that support and expand access to fertility services.
Filing targets: Executive Office of the President (EOP)
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Policies and future legislation related to drug labeling and chronic pain surveillance.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in the Coronavirus Aid, Relief, and Economic Security (CARES Act; Public Law 116-136); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2026 House and Senate appropriations for the Food and Drug Administration; skin cancer prevention for outdoor workers; use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA); nomination of new HHS and FDA leadership.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KINDERFARMS, LLC via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Over-the-counter (OTC) drug and food safety and nutrition issues; nomination of new HHS and FDA leadership; OTC monograph User Fee Act (OMUFA) reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2025 · first_quarter · Q1
Safe Act of 2025; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INCEPTION FERTILITY, LLC via HOLLAND & KNIGHT LLP
2025 · first_quarter · RR
Policies that support and expand access to fertility services.
KINDERFARMS, LLC via HOLLAND & KNIGHT LLP
2025 · first_quarter · RR
Over-the-counter drug and food safety and nutrition issues.
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); skin cancer prevention for outdoor workers; use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · 4A
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Supporting publication of FDA regulation regarding nutrition claims.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · Q4
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Funding for research on psychedelic drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · 4T
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL, INC. via HOLLAND & KNIGHT LLP
2024 · fourth_quarter · RR
Advocate for restoration of the full amount of the Orphan Drug Tax Credit.
Advocate for restoration of the full amount of the Orphan Drug Tax Credit.
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); skin cancer prevention for outdoor workers; Cancer Moonshot initiative; use of sunscreen in schools to prevent sunburns in children; reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
JOHNSON FOODS, LLC via HOLLAND & KNIGHT LLP
2024 · third_quarter · 3T
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Supporting publication of FDA regulation regarding nutrition claims.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Funding for research on psychedelic drugs; Discuss impact of psychedelic drugs on veterans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2024 · third_quarter · Q3
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction regarding the safety and efficacy and OTC sunscreen active ingredients; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration (H.R. 9027 and S. 4690); implementation of the National Academies of Science (NAS) report on sunscreen; skin cancer prevention for outdoor workers; Cancer Moonshot initiative; use of sunscreen in schools to prevent sunburns in children.
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NOMI HEALTH via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Secure/recoup funding for COVID testing; healthcare payment transparency; HR 4531/S.393 - The SUPPORT Act; find co-sponsors for Improving Seniors Timely Access to Care Act, S. 4532/H.R. 8702.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON FOODS, LLC via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Raising awareness about company's product pipeline; FDA regulation of dietary supplements; promoting support for S.3039/H.R. 5905 - Federal Kratom Consumer Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Supporting publication of FDA regulation regarding nutrition claims.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2024 · second_quarter · Q2
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
FDA regulation regarding nutrition claims.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction over determinations regarding the safety and efficacy and OTC status of sunscreens; sunscreen provisions in the FY 2025 House and Senate appropriations for the Food and Drug Administration; issues related to sunscreen use and coral reefs; implementation of the National Academies of Science (NAS) report on sunscreen; skin cancer prevention for outdoor workers; Cancer Moonshot initiative.
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SCIPHER MEDICINE CORPORATION via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Advocacy regarding test coverage.
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S. 2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; S.2922 - Advancing Research for Chronic Pain Act; S.3393/H.R. 4531 - Support for Patients and Communities Reauthorization Act.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NOMI HEALTH via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Vaccine dissemination and distribution; pandemic vaccine and testing policies; funding for COVID testing; healthcare payment transparency; HR 4531/S.393 - The SUPPORT Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs.
Funding for research on psychedelic drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2024 · first_quarter · Q1
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EKATERRA TEA MSO USA, LLC DBA LIPTON TEAS & INFUSIONS via HOLLAND & KNIGHT LLP
2024 · first_quarter · RR
FDA regulation regarding nutrition claims.
COMPASS PATHWAYS PLC via HOLLAND & KNIGHT LLP
2024 · first_quarter · RR
Funding for research on psychedelics.
Funding for research on psychedelics.
Funding for research on psychedelics.
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Implementation and reauthorization of the Food and Drug Administration (FDA) over-the-counter (OTC) drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on OTC sunscreen active ingredients; FDA jurisdiction over determinations regarding the safety and efficacy and OTC status of sunscreens; sunscreen provisions in the FY 2024 House and Senate appropriations for the Food and Drug Administration (H.R. 4368 and S. 2131); issues related to sunscreen use and coral reefs; implementation of the National Academies of Science (NAS) report on sunscreen; skin cancer prevention for outdoor workers; Cancer Moonshot initiative.
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UL LLC D/B/A UL SOLUTIONS via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
E-mobility and lithium-ion battery safety, cyber security for medical devices and US Cyber Trust Mark, clean energy, data privacy, PFAS, Embedded carbon, and Plastics.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOMI HEALTH via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Vaccine dissemination and distribution; pandemic vaccine and testing policies; funding for COVID testing; pharmacy benefit manager policies and oversight; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.1339 - Pharmacy Benefit Manager Reform Act; S.1967 - Patients Before Middlemen Act; HR 2400/S.1165 - The Reentry Act; healthcare payment transparency; HR 4531 and S.393 - The SUPPORT Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; Advancing Research for Chronic Pain Act, S. 2922.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation; Advancing Research for Chronic Pain Act, S. 2922.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
SCIPHER MEDICINE CORPORATION via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Advocacy regarding test coverage.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2023 · fourth_quarter · Q4
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Implementation of the over the counter drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Security (CARES Act); FDA proposed order on over-the-counter sunscreen ingredients; FDA jurisdiction over determinations regarding the safety and efficacy and OTC status of sunscreens; sunscreen provisions in the FY 2024 House and Senate appropriations for the Food and Drug Administration (H.R. 4368 and S. 2131); issues related to sunscreen use and coral reefs; implementation of the National Academies of Science (NAS) report on sunscreen; skin cancer prevention for outdoor workers; reauthorization of the FDA Over-the-Counter Monograph Drug User Fee program.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
UL LLC D/B/A UL SOLUTIONS via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
E-mobility and lithium-ion battery safety, cyber security for medical devices and US Cyber Trust Mark, clean energy, data privacy, PFAS, Embedded carbon, and Plastics.
NALU BIO, INC. via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Monitoring of the reauthorization of the Farm Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIPHER MEDICINE CORPORATION via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Advocacy regarding test coverage.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROTECTING ACCESS TO PAIN RELIEF COALITION via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation.
Policies related to labeling in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations legislation; chronic pain surveillance legislation.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NOMI HEALTH via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Vaccine dissemination and distribution; pandemic vaccine and testing policies; funding for COVID testing; pharmacy benefit manager policies and oversight; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.1339 - Pharmacy Benefit Manager Reform Act; S.1967 - Patients Before Middlemen Act; HR 2400/S.1165 - The Reentry Act; healthcare payment transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGITAL HEALTH FOR EQUITABLE HEALTH ALLIANCE via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Issues related to supporting use of digital technologies to improve health equity and reduce healthcare disparities; CONNECT for Health Act of 2023 (S.2016/H.R. 4189); Access to Prescription Digital Therapeutics Act (S.3791/H.R. 1458).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via HOLLAND & KNIGHT LLP
2023 · third_quarter · Q3
Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to hearing loss and treatment; H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027.
Issues related to hearing loss and treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to hearing loss and treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to hearing loss and treatment.